Pharmacia year-end results
This article was originally published in The Tan Sheet
Executive Summary
Consumer healthcare sales up 10.6% to $229 mil. in fourth quarter and 13.3% to $829 mil. for the year, "representing a second consecutive year of double-digit sales growth," firm reports Feb. 19. Gains were driven by "strong growth" in Nicorette smoking cessation franchise, which recorded sales increases of 15% in Q4 and 31% for the year. Pharmacia's total sales were flat at $3.74 bil. in the quarter and $13.99 bil. in 2002. On a reported basis, net earnings leapt to $554 mil. in Q4 from $86 mil. the previous year, spurred by one-time gain of $100 mil. from a patent infringement settlement with Allergan, $26 mil. from product licensing rights. Net earnings for 2002 dipped 60.2% to $1.5 bil. Firm's acquisition by Pfizer expected to close in Q1 2003 (1"The Tan Sheet" Jan. 27, 2003, p. 5)...
You may also be interested in...
Pfizer/Pharmacia Consumer Product Divestitures Addressing Overlaps – Exec
Overlapping consumer product categories appear to be delaying U.S. and EU regulatory approval of Pfizer's acquisition of Pharmacia
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.